0001209191-23-057220.txt : 20231204 0001209191-23-057220.hdr.sgml : 20231204 20231204163029 ACCESSION NUMBER: 0001209191-23-057220 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231130 FILED AS OF DATE: 20231204 DATE AS OF CHANGE: 20231204 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Domzalski David CENTRAL INDEX KEY: 0001727794 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38356 FILM NUMBER: 231463651 MAIL ADDRESS: STREET 1: C/O FOAMIX PHARMACEUTICALS LTD. STREET 2: 2 HOLZMAN STREET, WEIZMANN SCIENCE PARK CITY: REHOVOT STATE: L3 ZIP: 76704 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: VYNE Therapeutics Inc. CENTRAL INDEX KEY: 0001566044 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 453757789 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 685 ROUTE 202/206 N., SUITE 301 CITY: BRIDGEWATER STATE: NJ ZIP: 08807 BUSINESS PHONE: 800-775-7936 MAIL ADDRESS: STREET 1: 685 ROUTE 202/206 N., SUITE 301 CITY: BRIDGEWATER STATE: NJ ZIP: 08807 FORMER COMPANY: FORMER CONFORMED NAME: Menlo Therapeutics Inc. DATE OF NAME CHANGE: 20180201 FORMER COMPANY: FORMER CONFORMED NAME: Menlo Therapeutics, Inc. DATE OF NAME CHANGE: 20170728 FORMER COMPANY: FORMER CONFORMED NAME: Tigercat Pharma, Inc. DATE OF NAME CHANGE: 20130104 4 1 doc4.xml FORM 4 SUBMISSION X0508 4 2023-11-30 0 0001566044 VYNE Therapeutics Inc. VYNE 0001727794 Domzalski David C/O VYNE THERAPEUTICS INC. 685 ROUTE 202/206 N, SUITE 301 BRIDGEWATER NJ 08807 1 1 0 0 President and CEO 0 Common Stock 2023-11-30 5 A 0 E 2284 2.8135 A 46168 D These shares were acquired under the Issuer's Employee Share Purchase Plan ("ESPP") for the ESPP purchase period beginning on June 1, 2023 and ending on November 30, 2023 in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). In accordance with the terms of the ESPP, these shares were purchased at a price equal to 85% of the fair market value closing price of the Issuer's common stock on November 30, 2023 (the last trading day of the offering period). The reporting person purchased the maximum number of shares permitted by the terms of the ESPP during the calendar year. /s/ Mutya Harsch, attorney-in-fact for David Domzalski 2023-12-04